Literature DB >> 17081986

Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors.

Ding-Yen Lin1, Yen-Sung Huang, Jen-Chong Jeng, Hong-Yi Kuo, Che-Chang Chang, Ting-Ting Chao, Chun-Chen Ho, Yun-Ching Chen, Tong-Ping Lin, Hsin-I Fang, Chih-Chang Hung, Ching-Shu Suen, Ming-Jing Hwang, Kun-Sang Chang, Gerd G Maul, Hsiu-Ming Shih.   

Abstract

Small ubiquitin-like modifier (SUMO) modification has emerged as an important posttranslational control of protein functions. Daxx, a transcriptional corepressor, was reported to repress the transcriptional potential of several transcription factors and target to PML oncogenic domains (PODs) via SUMO-dependent interactions. The mechanism by which Daxx binds to sumoylated factors mediating transcriptional and subnuclear compartmental regulation remains unclear. Here, we define a SUMO-interacting motif (SIM) within Daxx and show it to be crucial for targeting Daxx to PODs and for transrepression of several sumoylated transcription factors, including glucocorticoid receptor (GR). In addition, the capability of Daxx SIM to bind SUMO also controls Daxx sumoylation. We further demonstrate that arsenic trioxide-induced sumoylation of PML correlates with a change of endogenous Daxx partitioning from GR-regulated gene promoter to PODs and a relief of Daxx repression on GR target gene expression. Our results provide mechanistic insights into Daxx in SUMO-dependent transcriptional control and subnuclear compartmentalization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17081986     DOI: 10.1016/j.molcel.2006.10.019

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  204 in total

1.  Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.

Authors:  Theodora E Danciu; Sergey Chupreta; Osvaldo Cruz; Jennifer E Fox; Malcolm Whitman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

Review 2.  The fate of metaphase kinetochores is weighed in the balance of SUMOylation during S phase.

Authors:  Debaditya Mukhopadhyay; Mary Dasso
Journal:  Cell Cycle       Date:  2010-08-09       Impact factor: 4.534

Review 3.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

4.  N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.

Authors:  Prashant Sharma; Rodolfo Murillas; Huafeng Zhang; Michael R Kuehn
Journal:  J Cell Sci       Date:  2010-03-16       Impact factor: 5.285

5.  Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins.

Authors:  José González-Santamaría; Michela Campagna; María Angel García; Laura Marcos-Villar; Dolores González; Pedro Gallego; Fernando Lopitz-Otsoa; Susana Guerra; Manuel S Rodríguez; Mariano Esteban; Carmen Rivas
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

6.  A novel proteomics approach to identify SUMOylated proteins and their modification sites in human cells.

Authors:  Frederic Galisson; Louiza Mahrouche; Mathieu Courcelles; Eric Bonneil; Sylvain Meloche; Mounira K Chelbi-Alix; Pierre Thibault
Journal:  Mol Cell Proteomics       Date:  2010-11-22       Impact factor: 5.911

7.  Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins.

Authors:  Huaiyu Sun; Joel D Leverson; Tony Hunter
Journal:  EMBO J       Date:  2007-08-30       Impact factor: 11.598

8.  Inhibition of CDK1 activity by sumoylation.

Authors:  Yuxuan Xiao; Benjamin Lucas; Elana Molcho; Tania Schiff; Margarita Vigodner
Journal:  Biochem Biophys Res Commun       Date:  2016-08-10       Impact factor: 3.575

9.  SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX.

Authors:  Sam R Holmstrom; Sergey Chupreta; Alex Yick-Lun So; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2008-06-18

10.  Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.

Authors:  Wei-Wei Pan; Jian-Jie Zhou; Xiao-Man Liu; Ying Xu; Lian-Jun Guo; Chao Yu; Qing-Hua Shi; Heng-Yu Fan
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.